Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

27.74 -0.26 (-0.93%)
Streaming Delayed Price Updated: 11:23 AM EDT, Sep 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
News headline image
2 Unprofitable Stocks for Long-Term Investors and 1 We Ignore
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv... 
Via StockStory
Topics Energy
News headline image
Securities Fraud Investigation Into Hims & Hers Health, Inc. (HIMS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Hims & Hers Responds to FTC Lawsuit
From Hims & Hers
Via Business Wire
News headline image
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HC... 
Via StockStory
News headline image
Why Is Hims & Hers Health Stock Surging on Thursday? ↗
Hims & Hers Health Inc (NYSE: HIMS) stock surges Thursday after an FDA advisory committee votes on adding BPC-157 to the allowed pharmacy compounding list. 
Via Benzinga
News headline image
1 Cash-Producing Stock to Target This Week and 2 Facing Headwinds
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cas... 
Via StockStory
News headline image
Here’s How Much You Would Have Made Owning Hims & Hers Health Stock In The Last 5 Years ↗
Hims & Hers Health (NYSE:HIMS) has outperformed the market over the past 5 years by 20.67% on an annualized basis producing an average annual return of 31.83%. Currently, Hims & Hers Health has a... 
Via Benzinga
News headline image
Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the Company
From Hims & Hers
Via Business Wire
News headline image
3 Reasons HIMS Has Explosive Upside Potential
Hims & Hers Health trades at $33.39 per share and has stayed right on track with the overall market, gaining 9.6% over the last six months. At the same time,... 
Via StockStory
News headline image
Lowey Dannenberg, P.C. Investigates Hims & Hers Health, Inc. for Alleged Tracking of User Data
From Lowey Dannenberg, P.C.
Via GlobeNewswire
News headline image
Hims & Hers to Announce Second Quarter 2026 Financial Results on August 10, 2026
From Hims & Hers
Via Business Wire
News headline image
1 Stock Under $50 with Exciting Potential and 2 Facing Challenges
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha... 
Via StockStory
News headline image
Hims & Hers Health vs. Teladoc Health: Which Healthcare Stock Is a Better Buy in 2026? ↗
One prioritizes rapid consumer growth and profitability; the other commands scale but faces concentration risk. 
Via The Motley Fool
News headline image
As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner ↗
Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near. 
Via MarketBeat
News headline image
Here’s How Much You Would Have Made Owning Hims & Hers Health Stock In The Last 5 Years ↗
Hims & Hers Health (NYSE:HIMS) has outperformed the market over the past 5 years by 17.4% on an annualized basis producing an average annual return of 28.89%. Currently, Hims & Hers Health has a... 
Via Benzinga
News headline image
Hims & Hers Stock Surges as Analysts Lift Price Targets ↗
Hims & Hers Health Inc (NYSE:HIMS) shares are rising on Wenesday after B of A Securities and Canaccord Genuity raised their respective price targets on the stock. 
Via Benzinga
News headline image
Here's How Much $100 Invested In Hims & Hers Health 5 Years Ago Would Be Worth Today ↗
Hims & Hers Health (NYSE:HIMS) has outperformed the market over the past 5 years by 14.14% on an annualized basis producing an average annual return of 25.67%. Currently, Hims & Hers Health has a... 
Via Benzinga
News headline image
2 Unpopular Stocks That Deserve a Second Chance and 1 We Question
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord... 
Via StockStory
News headline image
1 Surging Stock Worth Your Attention and 2 We Find Risky
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a ne... 
Via StockStory
Topics Supply Chain
News headline image
Hims & Hers Stock Jumps After Barclays Raises Price Target ↗
Hims & Hers Health (NYSE: HIMS) shares are climbing after Barclays reiterated its bullish stance and lifted its price target from $29 to $39. 
Via Benzinga
News headline image
Hims & Hers Stock Is Climbing Tuesday: What Investors Need To Know ↗
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher on Tuesday as the stock continues to rebound from recent profit-taking. 
Via Benzinga
News headline image
3 Market-Beating Stocks with Exciting Potential
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ... 
Via StockStory
News headline image
Great News: Wall Street Is Turning Bullish on This Troubled Telehealth Stock ↗
This telehealth stock has fallen hard, but its GLP-1 shift and global expansion could reshape the long-term story. Is the market too skeptical or still too optimistic? 
Via The Motley Fool
News headline image
Hims & Hers Names Dr. Anant Vinjamoori as Chief Medical Officer of Hims
From Hims & Hers
Via Business Wire
News headline image
1 Growth Stock Set to Flourishand 2 We Ignore
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil... 
Via StockStory
Topics Economy
News headline image
Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World’s Largest Consumer Health Platform
From Hims & Hers
Via Business Wire
News headline image
2 Unprofitable Stocks with Competitive Advantages and 1 Facing Headwinds
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
Via StockStory
News headline image
Is Hims & Hers Stock an Undervalued Stock to Buy? ↗
The healthcare industry is ripe for disruption. 
Via The Motley Fool
News headline image
Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners
From Hims & Hers
Via Business Wire
News headline image
Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders? ↗
Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes. 
Via MarketBeat
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
60 61 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.